STUDY OBJECTIVES: To describe our 5-year experience with a clinical pathway used to ensure the timely communication and evaluation of unsuspected radiologic findings (URFs) noted on clinically requested chest imaging. DESIGN: Prospective data collection on clinical practice. SETTING: Academically affiliated Veterans Affairs medical center. PARTICIPANTS: Pulmonary physicians, nurses, and radiologists. RESULTS: Over a period of 5 years, 1,629 URFs were referred to the pathway (from chest radiographs, 1,359 [83.4%]; from CT scans, 270 [16.6%]). Most URFs (78%) were nodules, with a specific diagnosis made in one third of URFs, and with a specific diagnosis thought to be clinically significant in another one third of URFs. The most common diagnosis was neoplasm, with over two thirds of these diagnoses being lung cancer. One third of lung cancers detected were either stage 1 or 2, with 1 in 17 of all URFs being stage IA lung cancer. The cost of the pathway was estimated at 28,600 dollars per year. CONCLUSIONS: URFs noted on chest imaging are frequently clinically significant, and a systematic approach to managing URFs, such as a clinical pathway, can significantly improve care in a large teaching hospital.
STUDY OBJECTIVES: To describe our 5-year experience with a clinical pathway used to ensure the timely communication and evaluation of unsuspected radiologic findings (URFs) noted on clinically requested chest imaging. DESIGN: Prospective data collection on clinical practice. SETTING: Academically affiliated Veterans Affairs medical center. PARTICIPANTS: Pulmonary physicians, nurses, and radiologists. RESULTS: Over a period of 5 years, 1,629 URFs were referred to the pathway (from chest radiographs, 1,359 [83.4%]; from CT scans, 270 [16.6%]). Most URFs (78%) were nodules, with a specific diagnosis made in one third of URFs, and with a specific diagnosis thought to be clinically significant in another one third of URFs. The most common diagnosis was neoplasm, with over two thirds of these diagnoses being lung cancer. One third of lung cancers detected were either stage 1 or 2, with 1 in 17 of all URFs being stage IA lung cancer. The cost of the pathway was estimated at 28,600 dollars per year. CONCLUSIONS: URFs noted on chest imaging are frequently clinically significant, and a systematic approach to managing URFs, such as a clinical pathway, can significantly improve care in a large teaching hospital.
Authors: Christopher G Slatore; Nanda Horeweg; James R Jett; David E Midthun; Charles A Powell; Renda Soylemez Wiener; Juan P Wisnivesky; Michael K Gould Journal: Am J Respir Crit Care Med Date: 2015-08-15 Impact factor: 21.405
Authors: Thomas H Urbania; Jennifer R Dusendang; Lisa J Herrinton; Stacey Alexeeff; Douglas A Corley; Sora Ely; Ashish Patel; Todd Osinski; Lori C Sakoda Journal: Chest Date: 2020-06-17 Impact factor: 9.410
Authors: Christopher G Slatore; Nancy Press; David H Au; J Randall Curtis; Renda Soylemez Wiener; Linda Ganzini Journal: Ann Am Thorac Soc Date: 2013-08
Authors: Renda Soylemez Wiener; Michael K Gould; Christopher G Slatore; Benjamin G Fincke; Lisa M Schwartz; Steven Woloshin Journal: JAMA Intern Med Date: 2014-06 Impact factor: 21.873
Authors: Jonathan Shelver; Chris H Wendt; Melissa McClure; Brian Bell; Angela E Fabbrini; Thomas Rector; Kathryn Rice Journal: J Am Coll Radiol Date: 2017-04-21 Impact factor: 5.532
Authors: Donald R Sullivan; Sara E Golden; Linda Ganzini; Lissi Hansen; Christopher G Slatore Journal: NPJ Prim Care Respir Med Date: 2015-04-16 Impact factor: 2.871